Bio-Rad’s Acquisition of Stilla Technology: A Game-Changer in Digital PCR
In an exciting development for the life sciences industry, Bio-Rad Laboratories, a leading provider of life science research and clinical diagnostic products, has announced its intention to acquire all equity interests of Stilla Technology, a privately held company specializing in single-cell analysis and digital PCR (polymerase chain reaction) technologies. This strategic move is expected to expand Bio-Rad’s current digital PCR portfolio and strengthen its position in the rapidly growing field of single-cell analysis.
Stilla Technology: A Pioneer in Digital PCR
Stilla Technology, based in Menlo Park, California, has been a pioneer in the digital PCR market since its inception. Their flagship product, the S1000 system, offers high-performance, single-cell sensitivity, and high-throughput capabilities, making it an attractive addition to Bio-Rad’s existing portfolio. Digital PCR is a powerful tool for quantifying nucleic acids, providing precise and absolute quantitation of target molecules in complex samples, even in the presence of inhibitors and other interfering substances.
Complementing Bio-Rad’s Existing Digital PCR Offerings
Bio-Rad’s current digital PCR offerings include the ddPCR™ System, which provides high-resolution quantification of nucleic acids, and the qPCR Probe Library, which offers a comprehensive collection of assays for various applications. The acquisition of Stilla Technology will allow Bio-Rad to expand its digital PCR product line, offering customers a broader range of solutions tailored to their research needs.
Impact on the Life Sciences Community
The acquisition of Stilla Technology by Bio-Rad is expected to have a significant impact on the life sciences community. With the combined expertise and resources of both companies, researchers will have access to advanced digital PCR technologies that enable high-resolution quantitative analysis of single cells, offering new insights into various fields, including cancer research, immunology, and diagnostics.
Impact on the Wider World
Beyond the life sciences community, the acquisition of Stilla Technology by Bio-Rad could have far-reaching implications. Digital PCR technology has the potential to revolutionize industries such as agriculture, environmental monitoring, and forensics, enabling precise and accurate analysis of genetic material in complex samples. The expanded Bio-Rad digital PCR portfolio could open new opportunities for collaboration and innovation in these areas.
Conclusion
The acquisition of Stilla Technology by Bio-Rad is an exciting development for the life sciences industry and beyond. By combining Stilla Technology’s innovative digital PCR solutions with Bio-Rad’s existing portfolio, researchers will have access to a broader range of tools for precise and accurate analysis of nucleic acids in complex samples. This acquisition is expected to drive new innovations and collaborations, ultimately leading to advancements in various fields, including cancer research, immunology, and diagnostics.
- Bio-Rad to acquire Stilla Technology, a pioneer in digital PCR
- Stilla’s S1000 system offers high-performance, single-cell sensitivity, and high-throughput capabilities
- Acquisition expands Bio-Rad’s digital PCR portfolio and strengthens position in single-cell analysis
- Impact on life sciences community: new insights in various fields
- Impact on wider world: potential for revolutionizing industries such as agriculture, environmental monitoring, and forensics
